Full Press Release Details
WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ.
H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ, May 19, 2026Event details:Date: Tuesday, May 19, 2026Time: 1:30pm ETLocation: NASDAQ
Participants may access a live webcast of the event by clicking the linkhere.
The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website atwww.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.
About Verrica Pharmaceuticals Inc.Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH®(VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH®(VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visitwww.verrica.com.